Enliven Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $440 |
Gross Profit | -79 | -79 | 363 | |
EBITDA | -26,988 | -24,525 | -25,908 | -22,651 |
EBIT | -27,068 | -24,603 | -25,987 | -22,728 |
Net Income | -23,156 | -19,950 | -22,738 | -19,370 |
Net Change In Cash | 0 | 0 | 0 | 440 |
Free Cash Flow | -12,215 | -20,437 | -23,381 | -12,496 |
Cash | 100,621 | 96,871 | 149,219 | 100,195 |
Basic Shares | 48,267 | 48,075 | 42,045 | 41,128 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -297 | -622 | -99 | -97 |
EBITDA | -81,932 | -38,576 | -24,647 | -9,273 |
EBIT | -82,229 | -38,791 | -24,762 | -9,370 |
Net Income | -71,584 | -37,750 | -24,718 | -18,935 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -61,418 | -32,689 | -19,325 | -8,990 |
Cash | 100,141 | 75,536 | 110,024 | 130,365 |
Basic Shares | 35,546 | 6,248 | 7,814 | 3,481 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.47 |
2024-06-30 | -$0.41 |
2024-03-31 | -$0.54 |
2023-12-31 | -$0.47 |
